StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Benitec BioPharma (BNTC)

Tue, 06 Oct 2026 06:58:13 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $32.00 price target on Benitec BioPharma (NASDAQ: BNTC).

The analyst commented: "FDA feedback appears in line with expectations, potentially paving a registrational path forward for BB-301. Yesterday, Benitec Biopharma announced the receipt of formal feedback from the FDA following the conclusion of a Type C meeting in 3Q26. Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing; based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History Study. The FDA has agreed to review the relevant data on a timeline that

Benitec BioPharma (BNTC) Reiterated at Market Outperform by Citizens on Constructive FDA Interactions

Tue, 06 Oct 2026 05:14:16 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $24.00 price target on Benitec BioPharma (NASDAQ: BNTC).

The analyst commented, "Benitec Biopharma announced that the FDA has been constructive in interactions surrounding the company's planned single-arm pivotal study for BB-301 in oculopharyngeal muscular dystrophy (OPMD). The FDA provided positive feedback on the use of videofluoroscopic analysis to support the primary endpoint, but BNTC will need to confirm the final pivotal study design with the FDA, which is anticipated to occur in 1Q27. We maintain our Market Outperform rating and $24 DCF-derived price target ahead of our KOL call this week

Form 8-K Benitec Biopharma Inc. For: Oct 05

Mon, 05 Oct 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20261005/27146064.html

Benitec gets FDA feedback on BB-301 pivotal study design

Mon, 05 Oct 2026 08:01:06 -0400

Benitec Biopharma Inc. (NASDAQ: BNTC) announced it has received formal feedback from the U.S. Food and Drug Administration following a Type C meeting held in the third quarter of 2026, related to the planned pivotal study for its BB-301 therapy targeting oculopharyngeal muscular dystrophy (OPMD).

The FDA requested additional available data as part of ongoing discussions about an open-label, single-arm pivotal study design for BB-301, including data from the Benitec-sponsored OPMD Natural History Study. The agency agreed to review the submitted information on a timeline that would allow Benitec to confirm the final pivotal study design in the first quarter of

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

Mon, 05 Oct 2026 08:00:00 -0400

The BB-301 pivotal trial remains on track to begin in mid-2027
Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History Study
Final pivotal study design expected to be confirmed in 1Q 2027
Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients, at the European Society of

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

Mon, 05 Oct 2026 08:00:00 -0400

The BB-301 pivotal trial remains on track to begin in mid-2027
Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History Study
Final pivotal study design expected to be confirmed in 1Q 2027
Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients, at the European Society of

Form 8-K Benitec Biopharma Inc. For: Sep 29

Wed, 30 Sep 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260930/27128733.html

H.C. Wainwright Reiterates Buy Rating on Benitec BioPharma (BNTC)

Mon, 28 Sep 2026 07:04:41 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $32.00 price target on Benitec BioPharma (NASDAQ: BNTC).
The analyst commented: "We remind investors that Benitec Biopharma continues to advance BB-301 through clinical development in the ongoing Phase 1b/2a clinical study evaluating the safety and clinical efficacy of locally-administered BB-301 for the treatment of OPMD-related dysphagia. All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated. We draw investors' attention to the fact that clinically meaningful improvements (combined

Form 8-K Benitec Biopharma Inc. For: Sep 18

Thu, 24 Sep 2026 16:38:00 -0400
si-local-file:///var/storage/secattach/20260924/27102655.html

Form 10-K Benitec Biopharma Inc. For: Jun 30

Tue, 22 Sep 2026 17:10:00 -0400
si-local-file:///var/storage/secattach/20260922/27091823.html

Form EFFECT Benitec Biopharma Inc.

Tue, 22 Sep 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260922/27087121.html

Benitec BioPharma (BNTC) Reiterated at Market Outperform by Citizens on Business Update

Tue, 15 Sep 2026 04:33:51 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $24.00 price target on Benitec BioPharma (NASDAQ: BNTC).
The analyst commented, "Benitec issued an FY business update highlighting key upcoming events: 1) FDA interactions around pivotal trial design; 2) updated BB-301 data at ESGCT (October 27-30). We maintain our Market Outperform rating and $24 DCF-derived price target on Benitec Biopharma (BNTC) ahead of the key regulatory catalyst."
For an analyst ratings summary and ratings history on Benitec BioPharma click here. For more ratings news on Benitec BioPharma click here.
Shares of Benitec BioPharma closed at $12.08 yesterday.

Benitec Biopharma (BNTC) files $200M mixed shelf

Mon, 14 Sep 2026 17:13:15 -0400

Benitec Biopharma (NASDAQ: BNTC) filed $200,000,000 mixed shelf of:
Common Stock
Preferred Stock
Debt Securities
Warrants
Units

Benitec Biopharma (BNTC) files $200M mixed shelf

Mon, 14 Sep 2026 17:13:15 -0400

Benitec Biopharma (NASDAQ: BNTC) filed $200,000,000 mixed shelf of:
Common Stock
Preferred Stock
Debt Securities
Warrants
Units

Form S-3 Benitec Biopharma Inc.

Mon, 14 Sep 2026 17:10:00 -0400
si-local-file:///var/storage/secattach/20260914/27059265.html

Form 10-K Benitec Biopharma Inc. For: Jun 30

Mon, 14 Sep 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260914/27058486.html

Form 8-K Benitec Biopharma Inc. For: Sep 14

Mon, 14 Sep 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260914/27058372.html

Benitec Biopharma posts wider loss as BB-301 trial advances

Mon, 14 Sep 2026 16:00:55 -0400

Benitec Biopharma Inc. (NASDAQ: BNTC) reported a net loss of $45.5 million, or $0.98 per basic and diluted share, for the fiscal year ended June 30, 2026, compared with a net loss of $37.9 million, or $1.05 per share, for the prior year, according to a company press release.

Total operating expenses rose to $51.2 million from $41.8 million a year earlier. Research and development expenses increased to $23.4 million from $18.3 million, driven primarily by higher share-based compensation of $6.3 million and increased payroll of $2.2 million, partially offset by a $3.8 million reduction in contract manufacturing activity. General and

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

Mon, 14 Sep 2026 16:00:00 -0400

All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated
A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in October
Additional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breaking presentation at the Annual Congress of the European Society of

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

Mon, 14 Sep 2026 16:00:00 -0400

All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated
A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in October
Additional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breaking presentation at the Annual Congress of the European Society of

Wedbush Starts Benitec BioPharma (BNTC) at Outperform

Tue, 28 Jul 2026 06:46:48 -0400

Wedbush initiates coverage on Benitec BioPharma (NASDAQ: BNTC) with a Outperform rating and a price target of $16.00.
For an analyst ratings summary and ratings history on Benitec BioPharma click here. For more ratings news on Benitec BioPharma click here.
Shares of Benitec BioPharma closed at $11.58 yesterday.

Form 4 Benitec Biopharma Inc. For: Jun 29 Filed by: BUCHI J KEVIN

Tue, 30 Jun 2026 16:21:00 -0400
si-local-file:///var/storage/secattach/20260630/26713918.html

Form 4 Benitec Biopharma Inc. For: Jun 29 Filed by: BUCHI J KEVIN

Tue, 30 Jun 2026 16:21:00 -0400
si-local-file:///var/storage/secattach/20260630/26713918.html

Guggenheim Downgrades Benitec BioPharma (BNTC) to Neutral

Wed, 10 Jun 2026 06:47:16 -0400

Guggenheim analyst Debjit Chattopadhyay downgraded Benitec BioPharma (NASDAQ: BNTC) from Buy to Neutral.

For an analyst ratings summary and ratings history on Benitec BioPharma click here. For more ratings news on Benitec BioPharma click here.

Shares of Benitec BioPharma closed at $10.81 yesterday.

Form 8-K Benitec Biopharma Inc. For: May 22

Fri, 29 May 2026 16:11:00 -0400
si-local-file:///var/storage/secattach/20260529/26575218.html